DaVita (DVA)

Company ID: 166 | CIK: 0000927066
10-Q view:
No 10-K data
No 10-Q YTD data
No 10-Q 3M data
No 10-K data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-K data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
Segments are charted by their disclosed metrics (revenue, segment profit, etc.). Each line is a single segment. Reconciliation/corporate items are excluded. Major customers are shown as a percentage of revenue. Operational KPIs are grouped by metric concept; sub-metrics appear as separate lines.

Geographic Segments

Business Unit / Product Segments

Major Customers (% of Revenue)

Operational KPIs

Average revenue per treatment (arpu)

International dialysis centers (branches)

No 10-K data

Dialysis stations (capacity)

Total patient turnover (churn)

No 10-Q data

HCP members (customers)

HCP members under care (customers_served)

Employees (headcount)

Accounts receivable days (other)

Average Medicare rate per treatment (other)

No 10-Q data

Average dialysis and related lab services net revenue per treatment (other)

No 10-K data

Average dialysis and related lab services revenue per treatment (other)

No 10-Q data

Average dialysis revenue per dialysis treatment (other)

No 10-K data

Average dialysis revenue per treatment (other)

Average dialysis treatments per day (other)

No 10-Q data

Average dialysis treatments per treatment day (other)

Average effective interest rate (other)

No 10-K data

Average net revenue per treatment (other)

No 10-K data

Average patient care cost per treatment (other)

No 10-Q data

Average patient service revenue per treatment (other)

No 10-K data

Average repurchase price per share (other)

No 10-K data

Average revenue per treatment (other)

Average treatments per day (other)

Average treatments per normalized day (other)

No 10-K data

Average treatments per treatment day (other)

Bad debt provision ratio (other)

No 10-K data

Capitated member months (other)

No 10-K data

Care dollars under management (other)

No 10-Q data

Centers acquired (other)

Centers developed (other)

No 10-Q data

Centers opened (other)

No 10-K data

Clinical labor rate increase (other)

No 10-Q data

Clinical trial sites (other)

No 10-Q data

Commercial dialysis patients (other)

No 10-Q data

Commercial payor contracts (other)

No 10-Q data

Commercial payor revenue share (other)

Commercial revenue mix (other)

No 10-Q data

Commercial share of dialysis revenue (other)

No 10-Q data

Common shares outstanding (other)

Common stock outstanding (other)

Consolidated days sales outstanding (other)

No 10-K data

Countries of operation (other)

Countries with dialysis operations (other)

No 10-Q data

D&A ratio (other)

No 10-K data

DMG capitation revenue share (other)

No 10-Q data

DMG health plan concentration (other)

No 10-Q data

Day sales outstanding (other)

No 10-K data

Days in accounts receivable (other)

No 10-K data

Days of revenue in accounts receivable (other)

No 10-K data

Days of revenue in receivables (other)

No 10-K data

Days of revenue outstanding (other)

No 10-K data

Days revenue in accounts receivable (other)

No 10-K data

Days sales outstanding (other)

De novo break-even period (other)

No 10-K data

De novo facilities developed (other)

De novo facilities under development (other)

No 10-K data

Depreciation and amortization as % of revenue (other)

No 10-K data

Dialysis accounts receivable days (other)

No 10-Q data

Dialysis and related lab services revenue estimating risk (other)

No 10-Q data

Dialysis centers acquired (other)

Dialysis centers developed (other)

No 10-Q data

Dialysis centers opened (other)

No 10-K data

Dialysis days sales outstanding (other)

Dialysis joint ventures (other)

Dialysis patients by payor type (other)

No 10-Q data

Dialysis patients covered by Medicare (other)

No 10-Q data

Dialysis revenue by modality (other)

No 10-Q data

Dialysis revenue by payor (other)

No 10-K data

Dialysis revenue by payor source (other)

No 10-Q data

Dialysis revenue mix (other)

No 10-Q data

Dialysis revenue payor mix (other)

No 10-K data

Dialysis revenue per treatment (other)

Dialysis treatments (other)

No 10-K data

EPO reimbursement rate (other)

No 10-K data

EPO reimbursement share (other)

No 10-K data

EPO revenue (other)

No 10-K data

EPO revenue share (other)

EPO revenues (other)

No 10-K data

EPO revenues as % of net patient revenues (other)

No 10-K data

EPO share of net patient revenues (other)

No 10-K data

EPO share of operating revenues (other)

No 10-Q data

EPO share of revenue (other)

No 10-Q data

EPO share of revenues (other)

No 10-K data

Earnings to fixed charges (other)

No 10-K data

Effective income tax rate (other)

No 10-K data

Effective income tax rate attributable to DaVita Inc. (other)

No 10-K data

Effective interest rate (other)

No 10-K data

Effective tax rate (other)

No 10-K data

Facilities acquired (other)

Facilities in development (other)

No 10-K data

Facilities with physician minority interests (other)

No 10-K data

Facility cost ratio (other)

No 10-K data

Facility operating expenses as % of revenue (other)

No 10-K data

G&A cost ratio (other)

No 10-K data

General and administrative expenses as % of revenue (other)

No 10-K data

Goodwill concentration (other)

No 10-K data

Government payor mix (other)

No 10-K data

Government payor patient mix (other)

No 10-Q data

Government payor revenue mix (other)

No 10-Q data

Government payor revenue share (other)

No 10-Q data

Government share of dialysis revenue (other)

No 10-Q data

Government-based patient share (other)

No 10-Q data

Government-based revenue share (other)

No 10-Q data

Government-covered dialysis patients (other)

No 10-Q data

Government-paid treatments (other)

No 10-Q data

HCP Commercial Member Months (other)

No 10-Q data

HCP Medicaid Member Months (other)

No 10-Q data

HCP Senior Member Months (other)

No 10-Q data

HCP associated group primary care physicians (other)

No 10-Q data

HCP health plan concentration (other)

No 10-K data

HCP member months (other)

HCP network hospitals (other)

No 10-Q data

HCP network primary care physicians (other)

No 10-Q data

HCP practices acquired (other)

No 10-K data

HCP total care dollars under management (other)

No 10-Q data

Hospital inpatient dialysis contracts (other)

No 10-Q data

Hospital inpatient hemodialysis revenue share (other)

No 10-Q data

Hospitals contracted (other)

No 10-Q data

Hospitals contracted for inpatient dialysis (other)

No 10-Q data

Hospitals served (other)

No 10-Q data

Hospitals served with inpatient dialysis (other)

No 10-Q data

Hospitals with inpatient contracts (other)

No 10-Q data

Hospitals with inpatient dialysis contracts (other)

No 10-Q data

Inpatient hospital contracts added (other)

No 10-Q data

Interest expense net of interest income as % of revenue (other)

No 10-K data

Interest rate swap notional (other)

No 10-K data

International countries of operation (other)

No 10-K data

International patient share (other)

No 10-K data

Joint venture revenue share (other)

Joint venture share of dialysis revenue (other)

No 10-K data

Joint ventures (other)

No 10-K data

Magan Medical Group member months (other)

No 10-K data

Managed care contracts (other)

No 10-Q data

Managed facilities (other)

No 10-Q data

Managed third-party centers (other)

No 10-Q data

Medicaid funded net patient revenues (other)

No 10-K data

Medicaid revenue share (other)

No 10-K data

Medicaid share of dialysis revenue (other)

No 10-Q data

Medicaid share of net patient revenues (other)

No 10-K data

Medicaid share of revenues (other)

No 10-K data

Medical director contracts (other)

No 10-Q data

Medical director physicians and groups (other)

No 10-Q data

Medical directors (other)

No 10-Q data

Medical directors contracted (other)

No 10-Q data

Medical directors under contract (other)

No 10-Q data

Medicare composite rate (other)

Medicare composite rate per treatment (other)

Medicare funded net patient revenues (other)

No 10-K data

Medicare payment rate (other)

No 10-Q data

Medicare payment suspension withheld (other)

No 10-K data

Medicare payor mix (other)

No 10-K data

Medicare primary payor mix (other)

No 10-K data

Medicare primary payor revenue mix (other)

No 10-K data

Medicare rate per treatment (other)

No 10-Q data

Medicare revenue share (other)

No 10-K data

Medicare share of dialysis revenue (other)

No 10-Q data

Medicare share of net patient revenues (other)

No 10-K data

Medicare share of revenues (other)

No 10-K data

Member months (other)

Minority interests as % of revenue (other)

No 10-K data

Nephrologist relationships (other)

No 10-Q data

Nephrologists (other)

No 10-Q data

Nephrologists referring patients (other)

No 10-Q data

Net new centers (other)

No 10-Q data

Net operating revenue per treatment (other)

No 10-K data

Net operating revenues per treatment (other)

Net revenue per treatment (other)

New centers opened (other)

New facilities under development (other)

No 10-K data

Non-acquired treatment growth (other)

No 10-Q data

Non-acute commercial payor share (other)

No 10-Q data

Normalized non-acquired treatment growth (other)

Normalized treatment days (other)

No 10-K data

Normalized treatment growth (other)

No 10-Q data

Number of Reportable Segments (other)

Operating income as % of revenue (other)

No 10-K data

Other payor funded net patient revenues (other)

No 10-K data

Other payor share of net patient revenues (other)

No 10-K data

Other payor share of revenues (other)

No 10-K data

Outpatient hemodialysis revenue share (other)

No 10-Q data

Outpatient hemodialysis share (other)

No 10-Q data

Outpatient market share (other)

No 10-Q data

Overall effective interest rate (other)

No 10-K data

Overall weighted average effective interest rate (other)

No 10-K data

Patient care cost (other)

No 10-Q data

Patient care cost per treatment (other)

Patient care costs per treatment (other)

No 10-K data

Patient payor mix (other)

No 10-Q data

Patient turnover rate (other)

No 10-Q data

Patients covered by Medicare (other)

No 10-Q data

Patients covered by government programs (other)

No 10-Q data

Patients outside US (other)

No 10-K data

Patients under government programs (other)

No 10-Q data

Payor mix (other)

Peritoneal and home-based hemodialysis revenue share (other)

No 10-Q data

Peritoneal dialysis patients (other)

No 10-Q data

Peritoneal dialysis share (other)

No 10-Q data

Pharmaceutical revenue mix (other)

No 10-Q data

Pharmaceutical revenue share (other)

Provision for doubtful accounts as % of revenue (other)

No 10-K data

Ratio of earnings to fixed charges (other)

No 10-K data

Referring nephrologists (other)

No 10-Q data

Revenue by modality (other)

No 10-Q data

Revenue by payor mix (other)

Revenue by service setting (other)

No 10-Q data

Revenue by treatment modality (other)

No 10-Q data

Revenue from controlled joint ventures (other)

No 10-K data

Revenue mix by setting (other)

No 10-Q data

Revenue payor mix (other)

No 10-K data

Revenue per treatment (other)

Revenue per treatment increase (other)

No 10-Q data

Revenues per treatment (other)

No 10-K data

Revolver drawn (other)

No 10-K data

Revolving credit availability (other)

No 10-K data

Same-center treatment growth (other)

No 10-Q data

Separately billable pharmaceutical revenue mix (other)

No 10-K data

Shares outstanding (other)

No 10-K data

Shares repurchased (other)

No 10-K data

State Medicaid and other government revenue mix (other)

No 10-K data

States of operation (other)

No 10-Q data

States operated (other)

No 10-Q data

States served (other)

No 10-Q data

States with dialysis centers (other)

No 10-Q data

States with operations (other)

No 10-Q data

Treatment days (other)

Treatment growth (other)

No 10-K data

Treatment growth rate (other)

Treatment mix (other)

No 10-Q data

Treatment volume growth (other)

No 10-Q data

Treatments per day (other)

No 10-K data

Treatments per treatment day (other)

No 10-K data

U.S. dialysis market share (other)

No 10-Q data

U.S. dialysis revenue by payor source (other)

No 10-Q data

U.S. dialysis revenue payor mix (other)

No 10-Q data

U.S. market share (other)

No 10-Q data

U.S. outpatient dialysis market share (other)

No 10-Q data

U.S. states with dialysis operations (other)

No 10-Q data

URR >= 65% (other)

No 10-Q data

Undrawn revolving credit facilities (other)

No 10-K data

Urea reduction ratio quality (other)

No 10-Q data

VA payor mix (other)

No 10-K data

Veterans Health Administration revenue mix (other)

No 10-K data

Veterans Health Administration revenue share (other)

No 10-K data

Weighted average effective interest rate (other)

No 10-K data

Working capital (other)

No 10-K data

Patients served (patients)

Treatment mix (procedures)

Outpatient dialysis facilities (properties)

Average center square footage (square_footage)

No 10-Q data

Outpatient dialysis centers (stores)

HCP Members (subscribers)

Non-acquired treatment growth (throughput)

Human capital disclosures. Workforce totals and demographics are point-in-time. Flow metrics use the year-to-date period for 10-Q and full year for 10-K. Workforce actions (RIFs, restructurings, acquisition-related changes) are listed in the table at the bottom.

Workforce Totals

No 10-Q data

Demographics

No 10-Q data
No 10-Q data
No 10-Q data
No 10-Q data
No 10-Q data
No 10-Q data
No 10-Q data
No 10-Q data

Workforce Breakdowns

No 10-Q data
No 10-Q data
No 10-Q data
No 10-Q data

HCM Metrics — Point-in-Time

No 10-Q data

HCM Metrics — Flow (Annual / YTD)

No 10-Q data

Workforce Actions

Period EndTypeStatusAffected% WorkforceAnnouncedExpected CompletionGeographySegment / FunctionChargeSourceNote
2026-06-30otherin_progressUnited States — CaliforniaU.S. dialysis clinicsMD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Union petitions filed at a number of the Company's California clinics; election results have been mixed, with elections and legal challenges at various stages. No affected-employee count or dates disclosed.
2026-03-31otherin_progressUnited States — CaliforniaU.S. dialysis clinicsMD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Union petitions filed at a number of California clinics; some elections won, others in voting stages with legal challenges. No affected-employee count disclosed.
2025-09-30otherin_progressCalifornia, United StatesU.S. dialysis clinicsMD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Petitions subject to legal challenges; no affected-employee counts or dates disclosed.
2025-09-30acquisition_additioncompletedUnited States and Brazil (international)U.S. dialysis and international dialysis operationsbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Includes Fresenius Brazil operations effective 2025-08-01; headcount added not disclosed.
2025-06-30otherin_progressUnited States — CaliforniaU.S. dialysis clinicsMD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Union petitions filed at ten California clinics; nine are at various voting stages and face legal challenges. No filing date or employee counts given.
2025-03-31otherin_progressUnited States — CaliforniaClinic operationsMD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Union petitions filed at nine California clinics; eight are at various voting stages and face legal challenges. No employee counts or dates disclosed.
2024-12-31plant_closurecompleted2022-07-012024-12-31United StatesU.S. dialysisUSD 72 (millions)MD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Ongoing capacity-closure program from strategic review begun Q3 2022; 2024 activity included 24 closed centers and 12 sold/closed centers in the U.S. Charges comprise losses on assets retired, lease terminations, impairments and accelerated depreciation; no employee-impact count disclosed. Company expects closures to return to pre-COVID levels in 2025.
2024-12-31acquisition_additioncompleted2024-03-052024-12-31International (Latin America, Asia Pacific)International operationsbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Includes consolidation of the APAC joint venture (DaVita Care Pte. Ltd.) effective 2024-11-01 and Fresenius operations in Chile, Ecuador and Colombia; aggregate consideration $561.8 million. No headcount added through acquisitions disclosed. A Brazil transaction (~$100 million) was expected to close mid-2025.
2024-12-31divestiture_reductioncompleted2024-12-31United StatesU.S. integrated kidney care (physician services)MD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Timing and headcount impact not disclosed in this filing
2024-12-31restructuringcompleted2022-Q42023-12-31United StatesGeneral and AdministrativeUSD 27 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Plan committed in Q4 2022 to increase efficiencies in G&A support functions. Expenses recognized in 2023.
2024-12-31restructuringcompleted2022-Q42023-12-31United StatesIntegrated Kidney CareUSD 1 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Plan committed in Q4 2022 to increase efficiencies in G&A support functions and other overhead costs. Expenses recognized in 2023.
2024-09-30plant_closurein_progressUnited StatesU.S. dialysisUSD 18 (millions)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		13 U.S. dialysis centers closed in Q3 2024 (20 YTD); closure charges of $18.3M in Q3 ($48.2M YTD). No employee count disclosed; company expects elevated closure rates through remainder of 2024.
2024-09-30otherin_progressUnited States (California)U.S. dialysis clinicsMD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Union petitions filed at nine California clinics; eight in voting stages with legal challenges. A week-long attempted work stoppage at eight clinics concluded without impacting patient care.
2024-09-30acquisition_additioncompletedUnited States and InternationalU.S. dialysis and ancillary servicesbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		YTD 2024: acquired 12 U.S. and 91 international dialysis centers; noncontrolling interests assumed of $20.3M. No headcount added disclosed.
2024-09-30restructuringin_progress2022-09-30United StatesU.S. DialysisUSD 18 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Ongoing strategic review of outpatient clinic capacity resulting in center closures. Q3 2024 charges of $18.3M include net losses on assets, lease termination costs, and accelerated depreciation. Employee count not disclosed.
2024-09-30restructuringin_progress2022-09-30United StatesU.S. DialysisUSD 48 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		YTD 2024 charges for U.S. dialysis center closures totaled $48.2M. Employee count not disclosed.
2024-09-30restructuringcompleted2022-12-31United StatesU.S. DialysisMD&A
f5-10q / Qwen3.6-27B-Q8_0		Plan to increase efficiencies in G&A support functions. $26.3M recognized in YTD 2023; no specific charge disclosed for YTD 2024, implying completion or immateriality.
2024-09-30restructuringcompleted2022-12-31United StatesIntegrated Kidney CareUSD 0 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Efficiency plan in IKC business. $0.4M recognized in YTD 2023; no charge disclosed for YTD 2024.
2024-09-30otherin_progressCaliforniaU.S. DialysisMD&A
f5-10q / Qwen3.6-27B-Q8_0		Union petitions filed in 9 clinics; 8 in voting process. One week-long attempted work stoppage occurred in 8 clinics without impacting patient care.
2024-06-30plant_closurein_progress2024-12-31United StatesU.S. dialysisUSD 30 (millions)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Ongoing capacity-review program begun in Q3 2022. Six-month 2024 closure charges of $29.9M (Q2 2024: $15.3M; Q1 2024: $14.6M), covering patient care, G&A and D&A. 16 U.S. centers closed or sold in the six months ended June 30, 2024 (9 sold/closed, 7 closed with patients retained); 3 in Q2 2024. Charges include asset losses, lease terminations, impairments and accelerated depreciation. Headcount impact not disclosed. Management expects closure rates to remain elevated through the remainder of 2024.
2024-06-30plant_closurein_progressInternationalInternational operationsMD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Six international centers closed or sold during the six months ended June 30, 2024 (2 sold/closed, 4 closed with patients retained). No associated charge or headcount impact disclosed.
2024-06-30otherin_progressUnited StatesU.S. dialysis clinicsMD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Union organizing activity: petitions filed at certain Company clinics in California and at certain competitors' clinics, with some competitor clinics voting to unionize. Company is engaging with teammates; no employee counts, dates or election results for its own clinics disclosed.
2024-06-30acquisition_additioncompletedUnited States and internationalU.S. dialysis and international operationsbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		During the six months ended June 30, 2024 the Company acquired 12 U.S. and 90 international dialysis centers; cash paid net of cash acquired was $157.8M and goodwill of $137.8M was recognized. Headcount added through these acquisitions is not disclosed. Includes the Chile and Ecuador operations acquired from Fresenius Medical Care.
2024-06-30acquisition_additionannounced2024-03-05Colombia and BrazilInternational operationsother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Four purchase agreements signed with Fresenius Medical Care for dialysis operations in Chile, Ecuador, Colombia and Brazil. Chile and Ecuador closed in the first half of 2024; Colombia and Brazil were expected to close in the second half of 2024, subject to closing conditions and regulatory approval, with expected cash payments of approximately $180M. Headcount not disclosed.
2024-06-30restructuringin_progressUnited StatesU.S. DialysisUSD 15 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Center closure costs incurred in Q2 2024. Includes net losses on assets retired, lease termination costs, asset impairments, and accelerated depreciation. Employee count not disclosed.
2024-06-30restructuringin_progressUnited StatesU.S. DialysisUSD 30 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Cumulative center closure costs for the six months ended June 30, 2024. Employee count not disclosed.
2024-03-31plant_closurecompleted2024-03-31United StatesU.S. dialysisMD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		8 U.S. centers sold and/or closed where the majority of patients were not retained. Aggregate Q1 2024 U.S. center closure charges were $14.6M (patient care $3.3M, G&A $7.1M, D&A $4.2M); charge not broken out by closure type. No employee count disclosed.
2024-03-31plant_closurecompleted2024-03-31United StatesU.S. dialysisMD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		5 U.S. centers closed where the majority of patients were retained and transferred to existing centers. No employee count disclosed.
2024-03-31plant_closurecompleted2024-03-31InternationalInternational operationsMD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		4 international centers closed during the quarter. No employee count or associated charge disclosed.
2024-03-31acquisition_additioncompleted2024-03-31United StatesU.S. dialysisUSD 105 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		9 U.S. dialysis centers acquired; cash paid net of cash acquired $105.163M. Includes consolidation of a previously nonconsolidated U.S. partnership with a $35.1M non-cash gain. No employee headcount disclosed.
2024-03-31acquisition_additioncompleted2024-03-31InternationalInternational operationsUSD 105 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		67 international dialysis centers acquired. Cash paid figure of $105.163M is disclosed as a combined total with the U.S. centers and is not split by geography. No employee headcount disclosed.
2024-03-31acquisition_additionin_progress2024-03-052024-12-31Chile, Ecuador, Colombia, BrazilInternational operationsUSD 237 (millions)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Agreement with Fresenius Medical Care to acquire dialysis service operations in four countries; Chile completed March 2024, remaining three expected to close during 2024. Total cash payments approximately $237M. No employee headcount disclosed; possible overlap with the 67 international centers reported in Note 11.
2024-03-31otherin_progressUnited StatesU.S. dialysis — clinic operationsMD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Union organizing activity: petitions filed by a union at certain Company clinics in California, with certain competitor clinics subsequently voting to unionize. No filing dates, election results, or affected-employee counts disclosed for the Company's own clinics.
2024-03-31restructuringin_progressUnited StatesU.S. DialysisUSD 15 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Center closure costs including net losses on assets retired, lease costs, asset impairments, and accelerated depreciation. No employee count disclosed.
2024-03-31restructuringin_progressUnited StatesU.S. DialysisUSD 0 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Severance costs related to plan to increase efficiencies in G&A support functions. No employee count disclosed.
2024-03-31acquisition_additioncompletedUnited StatesU.S. Dialysisbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquired 9 U.S. dialysis centers. Employee count not disclosed.
2024-03-31acquisition_additioncompletedInternationalInternationalbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquired 67 international dialysis centers. Employee count not disclosed.
2023-12-31restructuringin_progress2022United StatesU.S. dialysis — general and administrative support functionsUSD 27 (millions)MD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Plan committed in Q4 2022 to increase efficiencies and cost savings; only the 2023 charge captured. Employees affected not disclosed.
2023-12-31restructuringin_progress2022United StatesU.S. integrated kidney care (IKC)USD 0 (millions)MD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Same Q4 2022 cost-savings plan; 2023 charge only. Employees affected not disclosed.
2023-12-31restructuringin_progress2022United StatesCorporate administrative supportUSD 1 (millions)MD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Rounded figure from the adjusted operating income reconciliation. Employees affected not disclosed.
2023-12-31plant_closurein_progress2022-07-01United StatesU.S. dialysis — outpatient center capacity optimizationUSD 99 (millions)MD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Strategic capacity review begun Q3 2022; 66 centers closed and 6 sold/closed in 2023 (patients largely retained). Charge includes closure costs only; employees affected not disclosed. Filer expects 2024 closure levels to remain elevated.
2023-12-31restructuringcompleted2022-Q4United StatesGeneral and AdministrativeUSD 27 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Plan to increase efficiencies in G&A support functions.
2023-12-31restructuringcompleted2022-Q4United StatesIntegrated Kidney CareUSD 0 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Plan to increase efficiencies in G&A support functions.
2023-12-31plant_closurecompleted2022-Q3United StatesU.S. DialysisUSD 99 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Center capacity closures including net losses on assets, lease costs, and impairments.
2023-09-30restructuringin_progress2022-12-31United StatesU.S. dialysis — general and administrative support functionsUSD 26 (millions)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Plan committed in Q4 2022 to increase efficiencies in G&A support functions; $26.3M of severance charges for the nine months ended 2023-09-30, including $4.3M in Q3 2023 and $5.0M in Q2 2023. No employee counts or completion date disclosed; announcement date approximated to Q4 2022.
2023-09-30plant_closurein_progress2022-09-30United StatesU.S. dialysis — outpatient center footprint optimizationUSD 67 (millions)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Strategic review of clinic capacity begun Q3 2022; 48 U.S. centers closed during the nine months ended 2023-09-30 (15 in Q3 2023). Charges of $67.3M YTD 2023 ($24.0M in Q3 2023) include losses on retired assets, lease costs, impairments and accelerated depreciation; no affected-employee counts disclosed. Filer expects elevated closure rates to continue.
2023-09-30restructuringin_progress2022-10-01United StatesU.S. DialysisUSD 24 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Center closure costs incurred in Q3 2023. Includes net losses on assets retired, lease costs, asset impairments, and accelerated depreciation. Employee count not disclosed.
2023-09-30restructuringin_progress2022-10-01United StatesU.S. DialysisUSD 4 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Severance costs related to plan to increase efficiencies in G&A support functions committed to in Q4 2022. Employee count not disclosed.
2023-09-30restructuringin_progress2022-10-01United StatesIntegrated Kidney CareUSD 0 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Severance costs for IKC business related to plan to increase efficiencies committed to in Q4 2022. Employee count not disclosed.
2023-06-30restructuringin_progressUnited StatesU.S. dialysis — general and administrative support functionsUSD 22 (millions)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Plan committed in Q4 2022 to increase efficiencies in G&A support functions; $21.9M severance charge YTD 2023 ($16.9M in Q1, $5.0M in Q2). No employee counts disclosed.
2023-06-30plant_closurein_progressUnited StatesU.S. dialysis — outpatient clinic capacity optimizationUSD 21 (millions)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q2 2023 charges for U.S. dialysis center closures; $43.3M YTD 2023. Company expects elevated closure rates over the next several quarters. No employee counts disclosed.
2023-06-30restructuringin_progress2022-10-01United StatesU.S. DialysisUSD 21 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Charges for U.S. dialysis center closures incurred in Q2 2023. Includes net losses on assets retired, lease costs, asset impairments, and accelerated depreciation.
2023-06-30restructuringin_progress2022-10-01United StatesU.S. DialysisUSD 5 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Severance costs related to plan to increase efficiencies in G&A support functions, announced in Q4 2022.
2023-06-30restructuringin_progress2022-10-01United StatesIntegrated Kidney CareUSD 0 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Severance costs for IKC business related to plan to increase efficiencies in G&A support functions, announced in Q4 2022. Charge recognized in Q1 2023.
2023-03-31restructuringin_progress2022-10-01United StatesU.S. dialysis — general and administrative support functionsUSD 17 (millions)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Plan committed in Q4 2022 to increase efficiencies in G&A support functions; Q1 2023 expense for termination and other benefit commitments. Employee count not disclosed.
2023-03-31plant_closurein_progress2022-07-01United StatesU.S. dialysis — outpatient clinic capacity optimizationUSD 22 (millions)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Strategic review of clinic capacity begun Q3 2022; Q1 2023 charges for center closures ($12.6M patient care, $4.8M G&A, $4.8M D&A). 20 U.S. centers closed during Q1 2023 per footprint table; associated employee count not disclosed. Company expects elevated closure rates over next several quarters.
2023-03-31restructuringin_progress2022-10-01United StatesU.S. integrated kidney care (IKC)USD 0 (millions)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Same Q4 2022 efficiency plan applied to IKC business; Q1 2023 termination and other benefit commitments. Employee count not disclosed.
2023-03-31restructuringin_progress2022-09-30United StatesU.S. DialysisUSD 22 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Strategic review of outpatient clinic capacity resulting in center closures. Charge includes net losses on assets retired, lease costs, asset impairments, and accelerated depreciation.
2023-03-31restructuringin_progress2022-12-31United StatesU.S. DialysisUSD 17 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Plan to increase efficiencies and cost savings in certain general and administrative support functions.
2023-03-31restructuringin_progress2022-12-31United StatesIntegrated Kidney CareUSD 0 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Plan to increase efficiencies and cost savings in certain general and administrative support functions and other overhead costs.
2022-12-31restructuringin_progressUnited StatesU.S. dialysisUSD 17 (millions)MD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Committed in the fourth quarter of 2022 to a plan increasing efficiencies and cost savings in certain G&A support functions; termination and other benefit commitments of $17 million recognized. Headcount affected not disclosed.
2022-12-31restructuringin_progressUnited StatesU.S. Integrated Kidney CareUSD 1 (millions)MD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Same fourth-quarter 2022 efficiency plan; amount rounds to zero in the non-GAAP reconciliation table. Headcount affected not disclosed.
2022-12-31restructuringin_progressInternationalInternational operationsUSD 8 (millions)MD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Fourth-quarter 2022 plan; $7.5 million covers severance and other charges, of which the non-GAAP reconciliation shows $5 million as severance and other costs. Headcount affected not disclosed.
2022-12-31restructuringin_progressUnited StatesCorporate administrative supportUSD 1 (millions)MD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Corporate component of the fourth-quarter 2022 efficiency plan; consolidated severance and other costs totaled $23 million for FY2022. Headcount affected not disclosed.
2022-12-31plant_closurein_progressUnited StatesU.S. dialysisUSD 86 (millions)MD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2022 capacity optimization: 112 U.S. centers closed with patients retained and 22 centers sold/closed without patient retention (net decrease of 91 U.S. centers). Charge comprises $21M patient care, $19M G&A and $46M D&A. Company expects elevated closure rates over the next several quarters. Employees affected not disclosed.
2022-12-31plant_closurecompletedInternationalInternational operationsMD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2022: 9 international centers sold/closed and 2 closed, against 11 acquired and 6 developed (net increase of 11). Employees affected not disclosed.
2022-12-31restructuringcompleted2022-10-01United StatesGeneral and AdministrativeUSD 17 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Plan to increase efficiencies in G&A support functions; $17M severance recognized in Q4 2022.
2022-12-31restructuringcompleted2022-10-01United StatesIntegrated Kidney CareUSD 1 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Efficiencies in G&A support functions; $0.5M severance recognized in Q4 2022.
2022-12-31restructuringcompleted2022-10-01InternationalGeneral and AdministrativeUSD 8 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Efficiencies in overhead costs; $7.5M severance and other costs recognized in Q4 2022.
2022-09-30plant_closurein_progressUnited StatesU.S. dialysisUSD 40 (millions)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q3 2022 charges of ~$40M for U.S. dialysis center capacity closures ($7M patient care, $12M G&A, $21M D&A); no employee count disclosed. Company expects elevated closure rates over the next several quarters.
2022-09-30otherin_progressUnited StatesCorporate / labor relationsUSD 51 (millions)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		YTD 2022 advocacy spend of ~$51M countering union policy efforts, including CA Proposition 29 ballot initiative voted on November 2022; Q3 alone ~$28M. Not a headcount action; captured as a material labor-relations event.
2022-09-30plant_closurein_progress2022-09-30United StatesU.S. dialysisUSD 40 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Third quarter charges for U.S. dialysis center closures were approximately $40 million, including net losses on assets retired, lease costs, asset impairments and accelerated depreciation. No specific employee count disclosed.
2021-12-31plant_closurecompletedUnited StatesU.S. dialysisMD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML		54 U.S. centers closed during 2021 where the majority of patients were retained and transferred to other centers; no employee counts or severance disclosed. Center count fell from 2,816 to 2,815.
2021-12-31plant_closurecompletedUnited StatesU.S. dialysisMD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML		11 U.S. centers sold and/or closed where the majority of patients were not retained; no employee counts disclosed.
2021-12-31plant_closurecompletedInternationalInternational operationsMD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML		5 international centers sold and/or closed during 2021 with majority of patients not retained; no employee counts disclosed.
2021-12-31plant_closurecompletedInternationalInternational operationsMD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML		1 international center closed during 2021 with majority of patients retained; no employee counts disclosed.
2021-12-31acquisition_additioncompletedUnited StatesU.S. dialysisMD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML		19 U.S. dialysis centers acquired during 2021; associated headcount not disclosed. Aggregate 2021 acquisition consideration was $212.1 million (Note 21).
2021-12-31acquisition_additioncompletedInternationalInternational operationsMD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML		17 international dialysis centers acquired during 2021; associated headcount not disclosed.
2021-12-31acquisition_additioncompleted2021-12-312021-12-31United StatesU.S. ancillary services (transplant software)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of transplant software business MedSleuth closed on the last day of fiscal 2021; headcount not disclosed.
2020-12-31divestiture_reductioncompleted2020-05-012020-05-01United StatesVascular access services (RMS Lifeline)USD 16 (millions)MD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Sale of 100% of Lifeline stock effective 2020-05-01 with a loss of approximately $16 million; no employee count disclosed. Company retained certain liabilities including those related to an ongoing U.S. Attorney investigation.
2020-12-31othercompleted2020-06-302020-06-30United StatesCorporate administrative support — senior executive leadershipMD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Severance accruals recorded in Q2 2020 tied to a senior executive leadership transition; no employee count or severance amount separately disclosed.
2020-12-31acquisition_additioncompleted2020-12-312020-12-31United States and international (10 countries)U.S. dialysis and international dialysis operationsUSD 182 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Eight U.S. and 66 international dialysis centers acquired during 2020 for $182.0 million net cash plus earn-outs; no acquired headcount disclosed.
2020-12-31restructuringcompleted2020-06-30United StatesCorporateMD&A
f5-10k / Qwen3.6-27B-Q8_0		Severance accruals recorded in Q2 2020 associated with senior executive leadership transition.
2020-09-30othercompleted2020-10-012021-01-31United StatesCorporate AdministrationUSD 487,500 (units)other
f5-10q / Qwen3.6-27B-Q8_0		Transition agreement for LeAnne Zumwalt (former CFO) executed Oct 1, 2020. Includes $450k success bonus and $37.5k healthcare reimbursement. Employment ends Jan 31, 2021.
2020-06-30divestiture_reductioncompleted2020-05-012020-05-01United StatesVascular access (RMS Lifeline, Inc.)USD 16,252 (thousands)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Sale of 100% of Lifeline stock effective 2020-05-01 with a pre-tax loss of $16,252 thousand; no employee count disclosed. Company retained certain liabilities including those related to an ongoing U.S. Attorney Colorado investigation.
2020-06-30acquisition_additioncompleted2020-06-302020-06-30United States and international (10 countries)Dialysis centersbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Six-month 2020 acquisitions comprised three U.S. and 25 international dialysis centers for $44,267 thousand net cash plus deferred and earn-out obligations; no headcount added disclosed. Announcement date is a placeholder for the period, as individual closing dates were not stated.
2020-06-30otherin_progress2020-04-01United StatesCorporate administrative supportMD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Severance and long-term compensation accruals tied to a senior executive leadership transition increased in Q2 2020 versus Q1 2020; no employee count or discrete charge amount disclosed. Announcement date is a placeholder for the quarter.
2020-06-30othercompleted2020-06-30United StatesCorporate Administrative SupportUSD 35 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Recorded net charge for legal matters included in general and administrative expenses.
2020-06-30othercompleted2020-06-30United StatesCorporate Administrative SupportMD&A
f5-10q / Qwen3.6-27B-Q8_0		Increase in severance accruals associated with senior executive leadership transition.
2020-03-31acquisition_additioncompletedUnited States and international (10 countries)U.S. dialysis and international dialysisbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q1 2020 acquisitions of two U.S. dialysis centers and 22 dialysis centers outside the U.S. for $34.1M net cash; no headcount added disclosed.
2019-12-31divestiture_reductioncompleted2019-06-192019-06-19United StatesDaVita Medical Group (integrated healthcare delivery and management)discontinued_operations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Sale of DMG to Optum closed 2019-06-19; DMG reported as discontinued operations for all periods. No employee headcount associated with the divestiture was disclosed.
2019-12-31restructuringcompleted2018-06-302018-12-31United StatesPharmacyUSD 11 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Restructuring of pharmacy business including transition of customer service and fulfillment functions to third parties and closure of distribution operation. Charge recognized in 2018.
2019-12-31divestiture_reductioncompleted2019-06-192019-06-19United StatesDaVita Medical Groupdiscontinued_operations_footnote
f5-10k / Qwen3.6-27B-Q8_0		Sale of DaVita Medical Group (DMG) business to Optum. Results reported as discontinued operations.
2019-06-30divestiture_reductioncompleted2017-12-052019-06-19United StatesDaVita Medical Group (DMG) — discontinued operationsother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Sale of DMG division to Collaborative Care Holdings, LLC (Optum) closed June 19, 2019 for an aggregate purchase price of $4,340,000 thousand. No employee headcount associated with the divested business is disclosed in this filing.
2019-06-30acquisition_additioncompleted2019-06-30United States and international (5 U.S. centers, 7 centers outside the U.S.)U.S. dialysis and related lab services; international kidney carebusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		During the six months ended June 30, 2019 the Company acquired 12 dialysis centers for $63,945 thousand net cash plus deferred and earn-out obligations. No acquisition-related headcount added is disclosed.
2019-03-31divestiture_reductionannounced2017-12-012019-06-30United StatesDaVita Medical Group (DMG)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Pending sale of DMG to Optum; agreement signed December 2017, contractual termination date 2019-06-30. No employee count disclosed for the divested workforce.
2019-03-31acquisition_additioncompletedUnited States and internationalU.S. dialysis and related lab servicesbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Four dialysis centers acquired during Q1 2019 (two U.S., two non-U.S.); no headcount added disclosed.
2019-03-31acquisition_additioncompletedUnited StatesDaVita Medical Group (DMG)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		One medical practice acquired by DMG during Q1 2019; no headcount added disclosed.
2018-12-31restructuringcompleted2018-06-302018-12-31United StatesAncillary services — DaVita Rx pharmacy businessUSD 11 (millions)MD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Customer service and fulfillment functions transitioned to third parties and distribution operation wound down in second half of 2018; separate asset impairment charges of $17 million also recognized. No employee count disclosed. Announcement date not specified; second-half 2018 date used as approximation
2018-12-31divestiture_reductioncompleted2018-06-012018-06-01United StatesAncillary services — Paladina Health (direct primary care)Item_1_Business
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Gain of approximately $34 million recognized on the transaction; headcount removed not disclosed
2018-12-31divestiture_reductionannounced12,6002018-12-112019-06-30United StatesDaVita Medical Group (DMG) divisionother
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Sale pending as of filing date (outside date June 30, 2019); employees_affected_count reflects disclosed DMG division headcount of approximately 12,600 teammates at December 31, 2018, not a filer-stated affected-employee figure. Original agreement entered December 2017; amendment date used as announcement date
2018-12-31acquisition_additioncompleted2018-12-312018-12-31United States and international (nine countries)Kidney Care — dialysis centersbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Aggregate purchase cost of approximately $240.0 million; headcount added through these acquisitions not disclosed. Announcement date not specified; fiscal year-end used as placeholder
2018-12-31restructuringcompleted2018-06-01United StatesPharmacy (DaVita Rx)USD 11 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Transitioned customer service and fulfillment functions of pharmacy business to third parties and ceased distribution operations. Recognized $11 million in restructuring charges and $17 million in asset impairment charges.
2018-12-31divestiture_reductioncompleted2018-06-01United StatesDirect Primary Care (Paladina Health)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Sold 100% of the stock of Paladina Health, direct primary care business.
2018-09-30restructuringin_progress2018-07-012018-12-31United StatesOther — Ancillary services and strategic initiatives (pharmacy services)USD 11 (millions)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Pharmacy business restructuring: transitioning customer service and fulfillment to third parties and winding down distribution operations. No employee count disclosed. Additional $6M asset impairment in Q3 2018 ($17M YTD); further restructuring charges expected in Q4 2018.
2018-09-30divestiture_reductionannounced2017-12-012018-12-31United StatesDaVita Medical Group (DMG)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Pending sale of DMG division to Optum (UnitedHealth Group); agreement entered December 2017, subject to regulatory approvals including FTC second request. Either party may terminate if not consummated by 2018-12-31 (with six-month extension option). No headcount associated with the divestiture disclosed.
2018-09-30restructuringin_progress2018-09-302018-12-31United StatesPharmacy ServicesUSD 11 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Plan to restructure pharmacy business, transitioning customer service and fulfillment to third parties and winding down distribution. Expected to continue incurring losses in Q4 2018.
2018-09-30restructuringin_progress2018-09-302018-12-31United StatesPharmacy ServicesUSD 6 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Asset impairment charges related to the pharmacy business restructuring plan.
2018-06-30restructuringannounced2018-07-012018-12-31United StatesPharmacy services (ancillary services and strategic initiatives)USD 11 (millions)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Asset write-off charge of $11M recognized in Q2 2018; plan to transition customer service and fulfillment to third parties and wind down distribution operation in H2 2018. Additional restructuring charges expected; no employee count disclosed.
2018-06-30divestiture_reductioncompleted2018-06-012018-06-01United StatesPaladina Health (direct primary care)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Sale of 100% of equity of DaVita DPC Holding Co., LLC effective June 1, 2018; initial estimated gain of $35,205 thousand. No headcount associated with the divestiture disclosed.
2018-06-30divestiture_reductionin_progress2017-12-012018-12-31United StatesDaVita Medical Group (DMG)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Pending sale of DMG division to Optum for $4.9 billion cash; expected to close in 2018 subject to regulatory approvals. No headcount associated with the divestiture disclosed.
2018-06-30restructuringin_progress2018-07-01United StatesPharmacyUSD 11 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Announced plan to restructure pharmacy business; recognized $11 million asset impairment charge in Q2 2018. Employee count not disclosed.
2017-12-31divestiture_reductionannounced2017-12-052018United States (southern California, central/south Florida, southern Nevada, central New Mexico, Colorado, Washington)DaVita Medical Group (DMG) divisionItem_1_Business
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Sale of DMG to Collaborative Care Holdings, LLC (Optum) for $4.9 billion in cash, subject to adjustments; employees affected not stated, though DMG employed approximately 12,400 teammates at 2017-12-31. DMG recorded goodwill and other asset impairment charges of $651.7 million in 2017 prior to reclassification as held for sale.
2017-12-31restructuringin_progressUnited StatesAncillary services — pharmacy business (DaVita Rx)USD 15 (millions)other
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Asset impairment charge of $15.168 million recognized in Q1 2017 related to restructuring of the pharmacy business; headcount affected and completion timeline not disclosed.
2017-12-31restructuringin_progressInternational (global, regional and country levels)International general and administrative infrastructureUSD 3 (millions)MD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Reorganization of international G&A infrastructure to improve efficiency; a further $1 million of equity investment losses related to restructuring charges at the APAC JV was also recognized in 2017. Employees affected not disclosed.
2017-12-31acquisition_additioncompleted2017-05-01United States (six states)U.S. dialysis and related lab servicesbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of 100% of Renal Ventures Management, LLC completed 2017-05-01 for approximately $359.9 million net cash; 36 dialysis centers, one uncertified center and one home program serving approximately 2,600 patients. Headcount added not disclosed. As a condition, three Renal Ventures centers plus three Company centers and one uncertified center were divested for approximately $21.2 million net cash.
2017-12-31plant_closurein_progressUnited StatesVascular access services (Lifeline)USD 35 (millions)other
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Partners and operators terminated management services agreements and closed centers following 2016/2017 CMS Physician Fee Schedule and ASC payment rule changes; goodwill of $28.4 million (2016) and $34.7 million (2017) impaired, with no goodwill remaining at 2017-12-31. Number of centers closed and employees affected not disclosed.
2017-12-31restructuringcompletedInternationalGeneral and AdministrativeUSD 3 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Reorganization of international G&A infrastructure at global, regional, and country levels to improve efficiency. Includes $1M equity investment loss related to restructuring at APAC JV.
2017-12-31restructuringcompletedUnited StatesPharmacyUSD 15 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Asset impairment related to restructuring of pharmacy business.
2017-09-30restructuringin_progressUnited StatesDMG (DaVita Medical Group) — all markets and corporateUSD 10 (millions)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Reduction in force across all DMG markets and corporate location; charge recorded in G&A during Q3 2017. No employee count or completion date disclosed.
2017-09-30restructuringin_progressInternationalInternational operations — global, regional and country G&AUSD 2 (millions)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Reorganization of international G&A infrastructure at global, regional and country levels to improve efficiency; related equity investment loss of $1M at APAC JV. No employee count disclosed.
2017-09-30restructuringcompletedGlobalDMG and InternationalUSD 12 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Includes $10M DMG reduction in force across all markets and corporate; $2M international reorganization of G&A infrastructure.
2017-09-30acquisition_additioncompleted2017-05-01United StatesU.S. dialysis and related lab servicesbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of Renal Ventures Management, LLC completed May 1, 2017. Headcount not explicitly disclosed.
2017-09-30acquisition_additioncompleted2017-07-01United StatesDMGbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of Magan Medical Clinic, Inc. effective July 1, 2017. Headcount not explicitly disclosed.
2017-03-31restructuringin_progressUnited StatesOther—Ancillary services and strategic initiatives (pharmacy services)USD 15 (millions)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Asset impairment charge for restructuring of the pharmacy business; no employee counts or severance amounts disclosed.
2017-03-31acquisition_additioncompletedUnited StatesDMG (DaVita Medical Group)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		During Q1 2017 DMG acquired one private medical practice and one primary care physician practice; headcount added not disclosed.
2017-03-31acquisition_additioncompleted2017-05-012017-05-01United States (Colorado and six states)U.S. dialysis and related lab servicessubsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Renal Ventures Management, LLC (38 outpatient dialysis centers) completed 2017-05-01 for approximately $360 million cash; seven centers required to be divested as part of the transaction. No employee counts disclosed.
2017-03-31acquisition_additioncompleted2017-03-31United StatesKidney CareMD&A
f5-10q / Qwen3.6-27B-Q8_0		Acquired 12 dialysis centers in the U.S. during Q1 2017. Headcount not disclosed.
2017-03-31acquisition_additioncompleted2017-03-31InternationalKidney CareMD&A
f5-10q / Qwen3.6-27B-Q8_0		Acquired 3 dialysis centers outside the U.S. during Q1 2017. Headcount not disclosed.
2017-03-31acquisition_additioncompleted2017-03-31United StatesDMGMD&A
f5-10q / Qwen3.6-27B-Q8_0		DMG acquired one private medical practice and one primary care physician practice. Headcount not disclosed.
2017-03-31acquisition_additionannounced2017-05-01United StatesKidney CareUSD 360 (millions)subsequent_events
f5-10q / Qwen3.6-27B-Q8_0		Completed acquisition of Renal Ventures Management, LLC (38 outpatient dialysis centers) on May 1, 2017. Required to divest 7 centers. Headcount not disclosed.
2016-12-31acquisition_additioncompleted2015-11-232016-03-01United States (Washington)DaVita Medical Groupbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of The Everett Clinic completed March 1, 2016; filing discloses 500 providers caring for more than 315,000 patients but no employee headcount added.
2016-12-31divestiture_reductioncompleted2016-06-01United States (Arizona)DaVita Medical GroupUSD 10 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Sale of DMG Arizona business completed June 1, 2016, resulting in a pre-tax loss of $10 million; no employee count disclosed.
2016-12-31divestiture_reductioncompleted2016-08-01Asia PacificInternational dialysis operationsbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Asia Pacific dialysis business deconsolidated August 1, 2016 after Khazanah and Mitsui acquired a 40% equity interest; no employee count disclosed.
2016-12-31divestiture_reductioncompleted2016-09-30United States (Nevada)DaVita Medical Group (hospice)USD 16 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Las Vegas Solari Hospice, acquired March 2013, was sold in September 2016; $16 million accrual recorded for potential damages and liabilities; no employee count disclosed.
2016-12-31othercompleted2016-11-30InternationalDaVita InternationalUSD 1,500 (thousands)other
f5-10k / MiMo-V2.6-Flash-fp8-HTML		CEO of DaVita International position eliminated as part of a reorganization effective November 30, 2016; $1.5 million lump-sum separation payment plus a three-year consulting agreement.
2016-12-31acquisition_additionannounced2016-08-092017-06-30United States (Colorado)U.S. dialysis and related lab servicesUSD 360 (millions)other
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Pending acquisition of 38 outpatient dialysis centers and a 51% interest in one vascular access clinic for approximately $360 million cash; expected to close mid-2017 subject to FTC clearance; no employee count disclosed.
2016-09-30divestiture_reductioncompleted2016-08-012016-08-01Asia PacificInternational dialysis operations (Kidney Care)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Deconsolidation of the APAC JV after Khazanah and Mitsui invested for a 40% equity interest; workforce removed from consolidation, but no employee count disclosed.
2016-09-30divestiture_reductioncompleted2016-092016-09United States (Nevada)DMG — Las Vegas Solari HospiceUSD 16,000 (thousands)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Hospice business acquired March 2013 and sold September 2016; associated accrual of $16.0 million relates to a self-disclosure matter, not severance. No headcount disclosed.
2016-09-30acquisition_additionannounced2016-08-09United States (Colorado)U.S. dialysis and related lab servicesbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Amended agreement to acquire Renal Ventures (38 outpatient dialysis centers plus a 51% interest in one vascular access clinic) for approximately $360 million cash; company expects close in early 2017 subject to FTC clearance. No employee count disclosed.
2015-12-31acquisition_additioncompletedUnited States and internationalDialysis and related lab services; ancillary servicesbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		2015 acquisitions comprised six U.S. dialysis centers, 21 international dialysis centers, three vascular access centers and other medical businesses; headcount added not disclosed.
2015-12-31acquisition_additionannounced2015-08-17United States (Colorado and six states)Kidney Care — dialysissubsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Renal Ventures Limited, LLC acquisition (~$415 million cash) expected to close in 2016; 36 clinics, approximately 2,400 patients; employee headcount not disclosed.
2015-12-31acquisition_additionannounced2015-11-23United States (Washington)HealthCare Partners — physician groupsubsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		The Everett Clinic Medical Group merger (~$385 million cash) expected to close in early 2016; 500 providers caring for over 315,000 patients; employee headcount not disclosed.
2014-12-31acquisition_additioncompletedUnited States and international (10 countries)Dialysis centers and other medical businessesUSD 272 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		During 2014 the company acquired 18 U.S. dialysis centers, 7 dialysis centers outside the U.S. and other medical businesses for $272.094 million net cash plus deferred purchase price and earn-outs of $23.781 million; headcount added through these acquisitions was not disclosed. Charge value shown is total acquisition consideration, not a severance charge.
2014-12-31plant_closurecompletedUnited StatesU.S. dialysis and related lab servicesMD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML		During 2014 the company sold one U.S. dialysis center, merged 16 centers and closed one center; associated workforce impact was not quantified. Center roll-forward table shows 16 centers closed for which patients were retained and 2 sold/closed without patient retention.
2013-12-31divestiture_reductioncompleted2012-12-122013-02-01United StatesHome infusion services (discontinued operations)discontinued_operations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Sale of HomeChoice Partners Inc. to BioScrip completed February 1, 2013; associated headcount not disclosed. HomeChoice had approximately $68 million of 2012 revenues.
2013-12-31acquisition_additioncompleted2013-12-31United States and international (10 countries)U.S. dialysis and related lab services; international dialysis operations; other medical businessesbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		During 2013 the Company acquired 26 U.S. dialysis centers, 38 dialysis centers outside the U.S. and other medical businesses for $310,394 thousand net cash plus $24,683 thousand deferred purchase price; headcount added not disclosed.
2013-12-31acquisition_additioncompleted2013-12-31United States (HCP service markets)HealthCare Partners (HCP)MD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML		HCP acquired an independent physician network organization, a hospice care business, an oncology and hematology physician practice, four primary care physician practices and one private medical practice during 2013; headcount added not disclosed.
2013-12-31acquisition_additioncompleted2012-11-01United StatesHealthCare Partners (HCP)Item 1. Business
f5-10k / Qwen3.6-27B-Q8_0		Acquisition of HCP completed Nov 1, 2012. HCP employs approx 460 associated group full-time primary care physicians directly or through groups, and contracts with approx 3,100 additional network primary care physicians. Total headcount added not explicitly quantified in employee count, but HCP is a major line of business.
2013-12-31divestiture_reductioncompleted2013-02-01United StatesAncillary Services (HomeChoice)Item 7. MD&A
f5-10k / Qwen3.6-27B-Q8_0		Sale of HomeChoice Partners Inc. completed Feb 1, 2013. Employee count not explicitly disclosed.
2012-12-31acquisition_additioncompleted2012-05-202012-11-01United States (southern California, central/south Florida, southern Nevada, New Mexico)HealthCare Partners (managed care / physician networks)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		HCP became a wholly-owned subsidiary on 2012-11-01 for approximately $4.70 billion; HCP results consolidated from that date. No employee headcount for HCP disclosed; HCP operated 184 medical clinics at 2012-12-31. Transaction expenses of $30.8 million recorded in 2012.
2012-12-31divestiture_reductioncompleted2012-12-122013-02-01United StatesInfusion therapy services (HomeChoice Partners)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Stock purchase agreement dated 2012-12-12; sale to BioScrip completed 2013-02-01 for $70 million cash plus up to 90% of $20 million contingent consideration. HomeChoice had approximately $68 million of 2012 revenues; no employee count disclosed. Reported as held for sale at 2012-12-31 and as discontinued operations for all periods presented.
2012-12-31acquisition_additioncompleted2012-12-31United States and international (8 countries)Dialysis centers and ancillary businessesbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		During 2012 the company acquired 93 U.S. dialysis centers, 13 dialysis centers outside the U.S., a direct primary care business, three physician group organizations and three vascular access centers for $648.3 million net cash; aggregate purchase price $654.4 million. No associated employee headcount disclosed.
2012-12-31acquisition_additioncompleted2012-11-012012-11-01United StatesHealthCare Partners (HCP)Item 1. Business
f5-10k / Qwen3.6-27B-Q8_0		Acquisition of HealthCare Partners Holdings, LLC completed on November 1, 2012. Specific headcount added not disclosed in this filing.
2012-12-31acquisition_additioncompleted2012-01-012012-12-31United StatesDialysisItem 7. MD&A
f5-10k / Qwen3.6-27B-Q8_0		Acquired 93 U.S. dialysis centers during 2012. Specific headcount added not disclosed.
2012-12-31acquisition_additioncompleted2012-01-012012-12-31InternationalDialysisItem 7. MD&A
f5-10k / Qwen3.6-27B-Q8_0		Acquired 13 international dialysis centers during 2012. Specific headcount added not disclosed.
2012-12-31divestiture_reductionannounced2012-12-122013-02-01United StatesHomeChoice Partners, Inc.subsequent_events
f5-10k / Qwen3.6-27B-Q8_0		Sale of HomeChoice Partners, Inc. completed on February 1, 2013. Specific headcount removed not disclosed.
2011-12-31acquisition_additioncompleted2011-09-022011-09-02United StatesDialysis and related lab servicesbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of DSI Renal Inc. added 113 outpatient dialysis centers serving approximately 8,000 patients in 23 states; no employee headcount added was disclosed. Approximately $21.7 million of transaction and integration costs were recorded in general and administrative expenses.
2011-12-31divestiture_reductioncompleted2011-09-022011-10-31United StatesDialysis and related lab servicesdiscontinued_operations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FTC consent order required divestiture of 30 outpatient dialysis centers (28 sold September 30, 2011; 2 additional sold October 31, 2011) to complete the DSI acquisition; no employee headcount removed was disclosed. A loss of approximately $4.756 million, net of tax, was recorded on the divestiture of historical DaVita centers.
2011-09-30acquisition_additioncompleted2011-09-022011-09-02United States (23 states)Dialysis and related lab servicesbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of DSI Renal Inc. (113 outpatient dialysis centers, ~8,000 patients); no employee headcount disclosed. ~$9.0M transaction and integration costs recorded in G&A.
2011-09-30divestiture_reductioncompleted2011-08-262011-10-31United StatesDialysis and related lab servicesbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		FTC consent order required divestiture of 30 centers to complete DSI acquisition; 28 centers sold 2011-09-30, 2 centers effective 2011-10-31. No employee counts disclosed; ~$83.6M expected cash consideration.
2011-03-31acquisition_additionannounced2011-02-042011-09-30United StatesDialysis and related lab servicesUSD 689 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement to acquire CDSI I Holding Company (DSI Renal) for ~$689.2M cash; DSI operates ~106 centers serving ~8,000 patients. No employee headcount disclosed; expected close Q3 2011 subject to FTC clearance and anticipated divestiture of some centers.
2011-03-31acquisition_additioncompletedUnited StatesDialysis and related lab servicesUSD 82 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquired 17 dialysis centers during Q1 2011 for aggregate purchase cost of $81.5M; noncontrolling interests assumed of $17.9M. No employee headcount added disclosed.
2010-12-31acquisition_additioncompletedUnited StatesDialysis and related lab servicesUSD 189 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		41 chronic dialysis centers acquired during 2010 for aggregate purchase cost of $188,951 thousand; employee headcount added not disclosed.
2010-12-31plant_closurecompletedUnited StatesDialysis and related lab servicesItem_1_Business
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Six centers sold and 18 centers closed during 2010; for the 18 closed centers the majority of patients were retained and transferred to other existing centers. Associated workforce reduction not disclosed.
2010-12-31acquisition_additionannounced2011-02-04United StatesDialysis and related lab servicesUSD 689 (millions)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Agreement to acquire DSI Renal, Inc. (approximately 106 centers, approximately 8,000 patients) announced after fiscal year-end; expected to close Q2 or Q3 2011, subject to FTC clearance with anticipated center divestitures. Employee headcount not disclosed.
2009-12-31acquisition_additioncompletedUnited StatesDialysis and related lab servicesUSD 88 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		19 chronic dialysis centers acquired during 2009 for aggregate purchase cost of $87,955 thousand; no employee counts disclosed. Also purchased additional ownership interests in several majority-owned joint ventures for $6,859 thousand.
2009-12-31plant_closurecompletedUnited StatesDialysis and related lab servicesItem_1_Business
f5-10k / MiMo-V2.6-Flash-fp8-HTML		During 2009 the company sold or closed eight centers and merged 16 centers into existing centers (patients transferred); no associated employee counts or charges disclosed.
2009-12-31othercompleted2009-11-302009-11-30United StatesDVA Renal Healthcare (compliance obligations)Item_1_Business
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Five-year corporate integrity agreement covering acquired Gambro centers expired 2009-11-30; final OIG report accepted 2010-02-16. No workforce reduction disclosed.
2008-12-31acquisition_additioncompletedUnited StatesDialysis and related lab servicesUSD 126 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Cash paid net of cash acquired for 2008 acquisitions, which included 20 chronic dialysis centers plus additional ownership interests in majority-owned joint ventures and an 80% interest in a vascular access clinic; no employee counts disclosed
2008-12-31plant_closurecompletedUnited StatesDialysis and related lab servicesMD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Nine dialysis centers sold or closed during 2008; no employee counts or charges disclosed
2008-12-31othercompletedUnited StatesDialysis and related lab servicesMD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Eight centers merged into other existing centers during 2008, with the majority of patients retained and transferred; workforce impact not quantified
2008-12-31othercompletedUnited StatesDialysis and related lab servicesMD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Operations ceased at one joint venture in which the company held a noncontrolling interest during 2008; no employee counts disclosed
2008-06-30acquisition_additioncompletedUnited StatesDialysis and related lab servicesMD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquired 6 dialysis centers during Q2 2008 (10 centers YTD); also opened 12 new centers, closed 4, merged 2, and discontinued administrative services to 1 center in the quarter. No employee counts associated with these actions are disclosed.
2007-12-31acquisition_additioncompletedUnited StatesDialysis operationsbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		16 chronic dialysis centers acquired during 2007; associated headcount not disclosed
2007-12-31acquisition_additioncompletedUnited StatesInfusion therapy services (HomeChoice Partners)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		85% of HomeChoice Partners acquired for $70.5 million in cash and deferred obligations; associated headcount not disclosed
2007-12-31divestiture_reductioncompletedUnited StatesDialysis operationsMD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Six dialysis centers sold or closed during 2007; associated headcount not disclosed
2007-12-31divestiture_reductioncompleted2007-11-30United StatesManagement and administrative servicesMD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML		In November 2007 a management and administrative services agreement covering 20 dialysis centers was terminated; company also discontinued services to 21 centers in 2007; associated headcount not disclosed
2006-12-31acquisition_additioncompletedUnited StatesDialysis operationsUSD 86 (millions)MD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML		26 dialysis centers acquired during 2006 (including two previously minority-held) for aggregate purchase cost of $86.2 million; no headcount associated with the acquisitions is disclosed.
2006-12-31divestiture_reductioncompleted2006-12-31United StatesDialysis operationsMD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML		14 centers divested, sold or closed during 2006, including three centers sold to Renal Advantage effective 2006-01-01 in connection with the DVA Renal Healthcare acquisition; no associated headcount disclosed.
2005-12-31acquisition_additioncompleted2004-12-062005-10-05United StatesDialysis servicesUSD 29 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of DVA Renal Healthcare (566 outpatient centers, ~43,000 patients) for ~$3.06B; ~$29M acquisition-related costs incurred through 2005-12-31. Headcount added not separately disclosed.
2005-12-31divestiture_reductioncompleted2005-10-042006-01-01United StatesOutpatient dialysis centersdiscontinued_operations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FTC consent order required divestiture of 69 centers and termination of two management services agreements; 71 centers divested in 2005 (70 to Renal Advantage plus one to a physician group), with three additional centers sold effective 2006-01-01. Headcount removed not disclosed; ~$330M cash consideration received.
2005-09-30acquisition_additioncompleted2004-12-062005-10-05United StatesDialysis servicesUSD 3,055 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Purchase price of $3.055 billion subject to final price adjustments; no employee count disclosed. Subsequent-event acquisition closed October 5, 2005; results consolidate from October 2005. Renamed DVA Renal Healthcare, Inc.
2005-09-30divestiture_reductioncompleted2005-10-042005-10-06United StatesOutpatient dialysis centersbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		FTC consent order dated October 4, 2005 required divestiture of 69 centers and termination of two management services agreements; 70 centers sold to Renal Advantage on October 6, 2005 for approximately $328 million cash consideration, plus approximately $95 million taxes on sale. Three additional centers pending Illinois approval. Divested centers represent about 6% of 2004 pro forma revenues; treated as discontinued operations from Q4 2005. No employee count disclosed.
2005-09-30acquisition_additioncompletedUnited StatesDialysis servicesUSD 122 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		During the nine months ended September 30, 2005, the company acquired dialysis businesses consisting of 42 centers for $121.725 million in cash and deferred purchase price obligations. No employee count disclosed; individual announcement dates not provided.
2005-09-30acquisition_additionannounced2005-10-05United StatesDialysis Servicessubsequent_events
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of Gambro Healthcare completed Oct 5, 2005. Headcount not disclosed. Risk factors note potential turnover and loss of medical directors.
2005-09-30divestiture_reductionannounced2005-10-06United StatesDialysis Servicessubsequent_events
f5-10q / Qwen3.6-27B-Q8_0		Sale of 70 outpatient renal dialysis centers to Renal Advantage Inc. completed Oct 6, 2005. Headcount not disclosed.
2004-12-31acquisition_additionannounced2004-12-06United StatesDialysis servicesUSD 3,050 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Purchase price approximately $3.05 billion in cash (including ~$1.7 billion cash price and assumption of ~$1.3 billion intercompany debt). Closing subject to Hart-Scott-Rodino antitrust review; FTC second request received 2005-02-18. No employee headcount disclosed for the acquired business.
2004-12-31acquisition_additioncompletedUnited StatesDialysis servicesUSD 267 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		During 2004 the company acquired 51 chronic dialysis centers for an aggregate purchase cost of $266.7 million, including the ~$150 million purchase of Physicians Dialysis, Inc. (24 centers). No headcount added disclosed.
2004-12-31divestiture_reductioncompletedUnited StatesDialysis servicesbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Certain center operations divested for cash during 2004 ($1.2 million); 8 centers divested, closed or terminated during the year per Item 1 center-growth table. No headcount removed disclosed.
2004-09-30acquisition_additioncompletedDialysis centersbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Nine months ended 2004-09-30: 16 acquisitions of dialysis businesses comprising 45 centers for approximately $246,500 thousand cash; largest was Physicians Dialysis Inc. (PDI, ~$150,000 thousand, effective 2004-09-01, 24 centers). No employee headcount acquired is disclosed; $246,500 thousand is total purchase price, not a workforce charge.
2004-09-30othercompletedDialysis centersMD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Organic de novo growth: 7 new dialysis centers opened in Q3 2004 and 25 opened in the first nine months of 2004; no associated employee counts disclosed.
2004-06-30acquisition_additioncompleted2004-07-01United StatesDialysis centersUSD 60 (millions)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		July 2004 acquisition of 10 dialysis centers for approximately $60 million; no employee headcount disclosed for the acquired centers.
2004-06-30acquisition_additionannounced2004-07-222004-09-30United StatesDialysis centersUSD 150 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement to acquire Physicians Dialysis, Inc., which operates 24 centers, for approximately $150 million in cash; expected to close by end of Q3 2004. No employee headcount disclosed.
2003-12-31acquisition_additioncompletedUnited StatesDialysis center operationsUSD 84 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquired 27 chronic dialysis centers during 2003 for aggregate purchase cost of $84.102 million; headcount added not disclosed.
2003-12-31acquisition_additioncompletedUnited StatesAncillary services (vascular access management, disease management, clinical research)USD 21 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Aggregate 2003 purchase cost of $104.791 million less $84.102 million for dialysis centers equals $20.689 million for ancillary acquisitions, including a July 2003 vascular access management business (14 third-party physician practices) and an August 2003 disease management business. Headcount added not disclosed.
2003-12-31divestiture_reductioncompletedUnited StatesDialysis center operationsUSD 2 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Divested certain center operating assets totaling $2.275 million during 2003; associated headcount not disclosed.
2002-12-31divestiture_reductioncompleted2000-06-302002-06-30Puerto RicoDialysis operationsMD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Sale of remaining non-continental U.S. operations (Puerto Rico) completed in Q2 2002; headcount not disclosed. Prior-year divestitures of other non-continental operations completed in 2000.
2002-12-31acquisition_additioncompleted2002-12-31United StatesDialysis centersbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		11 dialysis centers acquired during 2002 for aggregate purchase price of $20,077 thousand; associated headcount not disclosed.
2002-12-31plant_closurecompleted2002-12-31United StatesDialysis centersItem_1_Business
f5-10k / MiMo-V2.6-Flash-fp8-HTML		12 centers divested, closed or terminated during 2002; associated workforce impact not disclosed.
2001-12-31acquisition_additioncompletedUnited StatesDialysis centersUSD 68 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		21 dialysis centers acquired during 2001 for an aggregate purchase price of $67,950 thousand; 16 of the acquired centers were previously managed by the Company. No employee headcount added is disclosed.
2001-12-31plant_closurecompleted2001-11-30United States (Minnesota)Clinical laboratoryItem_1_Business
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Minnesota laboratory operations closed in November 2001 and combined with the Florida laboratory; no employee count or charge disclosed.
2001-12-31divestiture_reductionannounced2000-12-312002-06-30Puerto RicoDialysis centersItem_1_Business
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Sale of two Puerto Rico centers under agreement signed in 2000; completion expected in Q2 2002 upon receipt of regulatory approvals and third-party consents. No employee count disclosed.
2000-12-31divestiture_reductioncompleted1999-10-012000-06-19Non-continental United States (Argentina, Germany, Italy, United Kingdom, Guam)Dialysis operationsUSD 83 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Impairment charge of $82.8M recorded in Q4 1999 for estimated losses on sale; divestitures substantially completed June 19, 2000, reducing non-continental centers from 84 to 2. No employee count disclosed for the divested operations.
2000-12-31acquisition_additioncompleted2000-12-31United StatesDialysis centersUSD 13 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		8 centers acquired during 2000 for aggregate purchase price of $12.895M; no employee headcount added disclosed. Additionally 11 centers developed and 8 new managed centers during 2000 per Item 1 center-growth table.
2000-12-31plant_closurecompleted2000-12-31United StatesDialysis centersUSD 5 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		111 terminations, closures and divestitures of centers during 2000 per Item 1 center-growth table; $5.2M impairment/valuation loss on continental U.S. operations in 2000. Closure losses averaged less than $1M per center. No employee counts disclosed.
2000-12-31divestiture_reductioncompleted1999-10-012000-06-30Non-continental U.S.Dialysis OperationsItem_1_Business
f5-10k / Qwen3.6-27B-Q8_0		Sold non-continental U.S. operations in 2000. Specific headcount reduction not disclosed.
2000-12-31plant_closurecompleted2000-01-012000-12-31Continental U.S.Dialysis CentersUSD 5 (millions)Item_1_Business
f5-10k / Qwen3.6-27B-Q8_0		Closed centers not supporting new strategic direction. Impairment losses averaged less than $1 million per center. Specific headcount not disclosed.
1999-12-31restructuringcompleted801998-02-271999-12-31United StatesGeneral and AdministrativeUSD 2 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Severance payments to approximately 80 RTC employees resulting from the 1998 merger. Costs recognized in 1998, liability balance reduced in 1999.
1999-12-31restructuringcompleted1998-02-271999-12-31United StatesExecutiveUSD 6 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Constructive termination of pre-existing employment contracts with RTC executive officers.
1999-09-30othercompletedUnited StatesCorporate / ExecutiveUSD 1,719,000 (units)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Executive severance expense of $1,719,000 recognized in Q3 1999 G&A; no employee count disclosed.
1999-09-30othercompletedUnited StatesCorporate / All employeesUSD 1,081,000 (units)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Employee retention program expense of $1,081,000 in Q3 1999 G&A, primarily for stock option exercise-period extensions after termination; no employee count disclosed.
1999-09-30othercompleted1999-08-041999-08-04United StatesExecutive (CEO/President)USD 766,580 (units)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Separation of officer effective 1999-08-04; $766,580 separation payment plus $9,000 legal fees; remained on Board of Directors.
1999-09-30othercompleted1999-07-161999-07-16United StatesExecutive (Officer)USD 180,000 (units)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Separation of officer effective 1999-07-16; $180,000 severance payable 2000-01-03; continued as consultant through 1999-12-31 or one week after CFO hire.
1999-09-30restructuringin_progress1998-02-271999-12-31United StatesCorporate / IntegrationUSD 4 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Remaining accrual for RTC merger integration includes $3.0M in severance/employment tax gross-ups expected by end of 1999 and $0.886M in lease payments for vacant lab space.
1999-09-30othercompleted1999-09-301999-09-30United StatesExecutive ManagementUSD 2 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		General and administrative expenses included approximately $1.719 million for executive severance.
1999-09-30othercompleted1999-09-301999-09-30United StatesCorporateUSD 1 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		General and administrative expenses included $1.081 million for an employee retention program, primarily for amendments to stock options.
1999-06-30restructuringin_progress1998-02-271999-12-31USD 4 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Remaining accrual for RTC merger integration includes $3.0M in severance/employment costs (tax gross-ups) and $0.985M in lease payments for vacant lab space. No employee count provided for remaining accrual.
1999-03-31restructuringin_progress1998-02-271999-06-30USD 4 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Remaining accrual for RTC merger integration costs, primarily tax gross-up payments and lease payments for vacant lab space.
1998-12-31acquisition_additioncompleted1998-02-271998-02-27United StatesDialysis operationsUSD 79 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		RTC merger completed 1998-02-27; added 185 facilities and ~13,200 patients; employee headcount added not disclosed. $79.4M initial merger and related costs recorded in Q1 1998.
1998-12-31restructuringcompleted801998-02-271998-12-31United StatesRTC administrative office and laboratoryUSD 2 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Approximately 80 RTC employees informed positions would be eliminated during merger integration; terminations structured through end of 1998; accrued severance ~$1.6M
1998-12-31voluntary_separationcompleted1998-02-271998-12-31United StatesRTC executive officersUSD 7 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		RTC merger constituted constructive termination under preexisting employment contracts; terminated RTC officers entitled to severance and tax gross-up payments of ~$6.5M; officer count not disclosed
1998-12-31restructuringcompleted801998-02-271998-12-31United StatesAdministrative and LaboratoryUSD 2 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Approximately 80 RTC employees informed positions would be eliminated; terminations structured over integration period through end of 1998. Accrued severance payments amounted to approximately $1.6 million.
1998-12-31restructuringcompleted1998-02-271998-12-31United StatesExecutive and Senior ManagementUSD 7 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Constructive termination of employment under preexisting contracts with RTC officers. Terminated officers entitled to severance payments and tax gross-up payments of approximately $6.5 million.
1998-09-30restructuringin_progress1998-02-27United StatesCorporate / OperationsUSD 45 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Merger integration costs include $45.26M for severance and employment agreements plus $25.995M for combining operations including elimination of duplicate departments; $21.711M accrual remained at quarter end; no employee count disclosed.
1998-09-30acquisition_additioncompleted1998-02-271998-02-27United StatesDialysis operationsbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Pooling-of-interests merger with RTC; 34,565,729 shares issued; no headcount added disclosed.
1998-09-30restructuringin_progress1998-02-27Corporate and OperationsUSD 45 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance and employment agreement payments related to the RTC merger. Employee count not disclosed.
1998-09-30restructuringin_progress1998-02-27OperationsUSD 26 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Costs to combine operations including elimination of duplicate departments and facilities. Employee count not disclosed.
1998-06-30acquisition_additioncompleted1998-02-271998-02-27United StatesDialysis operationsUSD 93 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Pooling-of-interests merger; no employee headcount added disclosed. Charge covers advisory, severance, and integration costs.
1998-06-30restructuringin_progress1998-02-27United StatesCorporate and operationsUSD 45 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Severance and employment agreement payments plus compensation plan costs as part of $92.8M merger charge; no employee count disclosed. $24.1M accrual remaining at quarter-end.
1998-06-30acquisition_additioncompleted1998-06-301998-06-30United StatesDialysis centers and pharmacyUSD 166 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		25 centers and additional partnership interests acquired in Q2 1998 for $166M cash; no headcount added disclosed.
1998-06-30acquisition_additionannounced1998-06-30United StatesDialysis facilitiesUSD 175 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		46 dialysis facilities completed or agreed post-quarter for ~$175M; no headcount added disclosed.
1998-06-30restructuringin_progress1998-02-27USD 45 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Merger-related severance and employment agreement payments. Total merger costs were $92.8 million, including $21.6 million transaction costs and $26.0 million integration costs.
1998-06-30othercompleted1998-02-27Executive Managementother
f5-10q / Qwen3.6-27B-Q8_0		Resignations of RTC Chairman/CEO Robert L. Mayer, Jr., EVP Frederick C. Jansen, CFO Ronald H. Rodgers, Jr., and General Counsel Thomas J. Karl following the Merger.
1998-03-31acquisition_additioncompleted1998-02-271998-02-27United StatesDialysis operationsUSD 93 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Pooling-of-interests merger with RTC; $92.8M total merger/integration charge including $45.26M for severance and employment agreements, $21.58M for advisory/legal/accounting costs, and $25.995M for combining operations. No employee headcount added disclosed.
1998-03-31restructuringcompleted1998-02-271998-03-31United StatesCorporate and operationsUSD 45 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Severance and employment agreement payments plus other compensation plan costs tied to the RTC merger. Includes officer resignations (CEO, EVP, CFO of RTC). No specific employee count disclosed.
1998-03-31restructuringcompleted1998-02-271998-03-31United StatesOperations — duplicate departments and facilitiesUSD 26 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Costs to combine operations including impairment of systems/equipment, elimination of duplicate departments and facilities. No employee count disclosed.
1998-03-31restructuringin_progress1998-02-27USD 45 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Payments under severance and employment agreements associated with the RTC Merger.
1998-03-31restructuringin_progress1998-02-27USD 26 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Costs to combine operations including elimination of duplicate departments and facilities.
1998-03-31othercompleted1998-02-27Executive ManagementRisk Factors
f5-10q / Qwen3.6-27B-Q8_0		Resignation of RTC Chairman/CEO Robert L. Mayer, Jr., EVP Frederick C. Jansen, and CFO Ronald H. Rodgers, Jr.
1997-12-31acquisition_additioncompleted1997-11-181998-02-27United StatesDialysis operationsItem_1_Business
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Merger with Renal Treatment Centers completed 1998-02-27, adding 185 facilities and ~13,200 patients. Employee headcount added not disclosed. Treated as pooling of interests.
1997-12-31othercompleted1998-02-271998-02-27United StatesExecutive leadership (RTC)Item_1_Business
f5-10k / MiMo-V2.6-Flash-fp8-HTML		RTC's Chairman/CEO/President, EVP, and CFO resigned post-merger, along with 'certain other officers' for whom the merger constituted constructive discharge. Total count not disclosed.
1997-03-31acquisition_additioncompletedUnited StatesDialysis centersUSD 8 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Purchased substantially all assets of three centers for about $8.1 million cash; no employee headcount disclosed for the acquired facilities.
1997-03-31acquisition_additionannouncedUnited StatesDialysis centersUSD 97 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		After 1997-03-31, completed or agreed to acquire 22 facilities for about $97.0 million, primarily funded by borrowings; no employee headcount disclosed.
1996-06-30acquisition_additioncompleted1996-03-01United StatesDialysis operations (Nephrology Services Business)USD 49 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Purchase of substantially all assets of Caremark International's Nephrology Services Business for $49 million cash; no employee count disclosed.
1996-06-30acquisition_additionannounced1996-06-30United StatesDialysis facilitiesUSD 33 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Post-quarter acquisition of eight facilities for $32.9 million ($32.1 million cash, remainder in stock); no employee count disclosed.
1996-03-31acquisition_additioncompleted1996-03-01United StatesDialysis operations (Nephrology Services Business)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Effective 1996-03-01 the Company acquired substantially all assets of Caremark International's Nephrology Services Business plus one South Carolina center; no employee headcount transferred was disclosed.
1996-03-31acquisition_additioncompleted1996-03-31United StatesDialysis operations (two existing dialysis companies)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Selected net assets of two dialysis companies purchased for $2.6 million and contributed to two general partnerships; no headcount disclosed.